Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 10/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26863449 | 0.88 | PIK3CA (0.35) | NOTUMPIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL30809287 | 0.83 | NOTUM (0.40) | NOTUMKDM1ANR1H2SCD5 | |
| SCHEMBL5959175 | 0.78 | NOTUM (0.40) | NOTUMPIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL15676941 | 0.77 | NOTUM (0.53) | NOTUMUSP2SMN1; SMN2KDM1AACLY | |
| SCHEMBL30898670 | 0.77 | NOTUM (0.53) | NOTUMUSP2SMN1; SMN2KDM1AACLY | |
| SCHEMBL31694150 | 0.76 | KDM1A (0.35) | NOTUMKDM1ANR1H2 | |
| SCHEMBL2123391 | 0.76 | PIK3CA (0.41) | PIK3CAUSP2SMN1; SMN2PIK3R1PIK3CD | |
| SCHEMBL29966436 | 0.76 | PIK3CA (0.40) | NOTUMPIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL28521491 | 0.76 | NR1H2 (0.42) | NOTUMPIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL22471426 | 0.76 | PIK3CA (0.40) | NOTUMPIK3CAUSP2SMN1; SMN2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | ZC3HAV1, ZC3HAV1L, IFNAR1 | NOTUM 517/4885PIK3CA 4659/4885USP2 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.